0001213900-17-002595.txt : 20170418 0001213900-17-002595.hdr.sgml : 20170418 20170320155855 ACCESSION NUMBER: 0001213900-17-002595 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Therapix Biosciences Ltd. CENTRAL INDEX KEY: 0001611746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1213 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: SCIENCE PARK, 18 EINSTIEN ST. STREET 2: P.O BOX 4122 CITY: NESS-ZIONA STATE: L3 ZIP: 7414002 BUSINESS PHONE: 972-8-9396577 MAIL ADDRESS: STREET 1: SCIENCE PARK, 18 EINSTIEN ST. STREET 2: P.O BOX 4122 CITY: NESS-ZIONA STATE: L3 ZIP: 7414002 CORRESP 1 filename1.htm

Therapix Biosciences Ltd.

5 Azrieli Center (Square Tower)

Tel-Aviv 6702501, Israel

March 20, 2017

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

	RE:	Therapix Biosciences Ltd. (CIK: 0001611746)
		Registration Statement No. 333-214458 on Form F-1 (the “Registration Statement”)

Ladies and Gentlemen:

Therapix Biosciences Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on March 21, 2017 at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.

	Very truly yours,

	Therapix Biosciences Ltd.

	By:	/s/ Dr. Elran Haber
		Dr. Elran Haber, Chief Executive Officer